Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Targeting NLRP3 Inflammasome-Induced Therapy Resistance in ALL

Zhongbo Hu, MD PhD, Michael Sporn, MD, John Letterio, MD

Blood (2020) 136 (Supplement 1): 46.

https://doi.org/10.1182/blood-2020-137520

Published: 2020

Journal Articles

Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-β Signaling Pathway

Ehsan Malek, MD, Sunjin Hwang, MD, Marcos de Lima, MD, Paolo Caimi, MD, Molly M Gallogly, MD PhD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Brenda Cooper, MD, James Driscoll, MD PhD, John Letterio, MD

Blood (2019) 134 (Supplement_1): 3232.

https://doi.org/10.1182/blood-2019-126728

Published: 2019

Journal Articles

Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Ehsan Malek, MD, Byung-Gyu Kim, PhD DVM, Jason Valent, MD, James Driscoll, MD PhD, Paolo Caimi, MD, Seong-Jin Kim, PhD, Marcos de Lima, MD, John Letterio, MD

Blood (2018) 132 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2018-99-112449

Published: 2018

Journal Articles

Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors

Byung-Gyu Kim, PhD DVM, Sung Hee Choi, PhD, George Luo, Olga Sergeeva, PhD, Zhenghong Lee, PhD, James Driscoll, MD PhD, Marcos de Lima, MD, Rose Beck, MD PhD, Seong-Jin Kim, PhD, John Letterio, MD, Ehsan Malek, MD

Blood (2018) 132 (Supplement 1): 1918.

https://doi.org/10.1182/blood-2018-99-117852

Published: 2018

Journal Articles

O -Fucose and Fringe-Modified Recombinant Notch Peptides As Decoy Molecules to Promote Hematopoietic Progenitor Mobilization

Lan Zhou, MD, Shuiliang Yu, PhD, Weihuan Wang, MD PhD, Marwah Albakri, Seunghwan Lim, Chris Siebel, PhD BA, Hillard M Lazarus, MD, John Letterio, MD, Wei Xin, MD PhD

Blood (2017) 130 (Supplement 1): 1903.

https://doi.org/10.1182/blood.V130.Suppl_1.1903.1903

Published: 2017

NARROW

Targeting NLRP3 Inflammasome-Induced Therapy Resistance in ALL

Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-β Signaling Pathway

Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors

O -Fucose and Fringe-Modified Recombinant Notch Peptides As Decoy Molecules to Promote Hematopoietic Progenitor Mobilization

Email alerts

ASH Publications

American Society of Hematology

Targeting NLRP3 Inflammasome-Induced Therapy Resistance in ALL

Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-β Signaling Pathway

Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide

Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors

O -Fucose and Fringe-Modified Recombinant Notch Peptides As Decoy Molecules to Promote Hematopoietic Progenitor Mobilization

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only